Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis
Adrian D. Vickers(RTI Health Solutions), David P. Carbone(Vanderbilt University), James A. Kaye(Rutgers, The State University of New Jersey), Min‐Hua Jen(Eli Lilly (United Kingdom)), Urpo Kiiskinen, Donald E. Stull(IQVIA (United States)), Katherine B. Winfree(Eli Lilly (United States)), Gebra Cuyún Carter(Eli Lilly (United States))
Cited by 35
Related Papers
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
|Cancer Cell|2004|1.1k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k